Primary endpoints: | |
1. To test if the percentage reduction of LEP amplitude 60 min post-drug administration differs in the tapentadol period as compared to the placebo period, at the non-sensitized forearm. | |
2. To test if the percentage reduction of PEP amplitude 60 min post-drug administration differs in the tapentadol period as compared to the placebo period, at the sensitized forearm. | |
Key secondary analyses of the primary endpoints: | |
1. To test if the percentage reduction of LEP amplitude 60 min post-drug administration differs in the pregabalin and/or lacosamide periods as compared to the placebo period, at the non-sensitized forearm. | |
2. To test if the percentage reduction of PEP amplitude 60 min post-drug administration differs in the pregabalin and/or lacosamide periods as compared to the placebo period, at the sensitized forearm. | |
3. To test if the percentage change in magnitude of theta oscillations 60 min post-drug administration differs in the tapentadol, pregabalin, and/or lacosamide periods as compared to the placebo period. |